NCT00165308View on ClinicalTrials.gov

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

March 31, 2004

Study Completion Date

June 30, 2009

Conditions
Hodgkin's DiseaseBreast Cancer
Interventions
DRUG

Tamoxifen

Given orally, daily for one year.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER